Swedbank AB sold 1,075 shares of Laboratory Co. of America Holdings (NYSE:LH), while UBS Group has lowered expectations for the stock price. However, Labcorp stock hit a 52-week high amid robust growth and was upgraded to Outperform on positive outlook on cost synergies. The company declared a quarterly cash dividend for 2025, confirmed its dividend of $0.72, and is set to pay a dividend. Despite some sell-offs, several institutions increased stock in Labcorp, including Janney Montgomery Scott LLC, KBC Group, Manning & Napier Advisors, and Oak Harvest Investment Services.
Financial results for Q4 2024 are set to be announced, with Q1, Q2, and Q3 results already shared. Recent acquisitions include select assets of Invitae and BioReference Health's Diagnostics Business. The company launched an H5 bird flu test amidst a US outbreak which should provide a positive impact on its stock price. Labcorp has also made a strategic partnership with Tufts Medicine and completed its spin-off of Fortrea while also announcing a comprehensive laboratory relationship with Legacy Health. However, concerns have been raised regarding Labcorp's debt and hidden liabilities associated with faulty paternity tests.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Sat, 01 Feb 2025 23:40:45 GMT - Rating 8 - Innovation 6 - Information 8 - Rumor 4
